A Survey of the Tardive Dyskinesia Induced by Antipsychotic Drugs in Patients with Schizophrenia
Objective: Tardive Dyskinesia (TD), is one of the important problems of the patients with schizophrenia. The emergence of these side effects depends on so many factors such as the patients' age and the duration of antipsychotic treatment. By discovering new drugs (Atypical), there has been an outstanding decrease in the emergence of these side effects. The present study investigates the symptoms of TD in the Patients with schizophrenia who were under treatments for more than 6 months.
Method: The sample of this study was 200 Patients with schizophrenia of four wards in Razi hospital (two acute and two chronic wards) who were hospitalized in the winter of 2006 and were qualified for this study. The subjects were 101 males and 99 females who were younger than 60 and had received antipsychotic drugs for at least 6 months. After psychiatric interview and filling the demographic questionnaire by the patients, the required information about the drugs and the intensity of the symptoms was acquired. Then clinical and physical examinations of tardive dyskinesia were done. Next, the tardive dyskinesia disorders' check list (AIMS) was used. Findings of this cross-sectional, descriptive study were analyzed by SPSS.There was a high ratio of 95% between TD and the age factor (P=0.05).
Results: There was no relationship between symptoms frequency and duration of treatment (P=0.68). Facial muscles and oral zones were mostly involved in T.D disorder (72%).
Conclusion: No significant difference was observed between nine fold symptoms of T.D in patients who were using traditional drugs and those who were using the new ones (typical and atypical). Findings showed that in the intensity of the symptoms, gender does not play a major role.
Sadock BJ, Kaplan HI, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2003.
Modestin J, Stephan PL, Erni T, Umari T. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 2000; 42: 223-230.
Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487.
Van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res 1996; 19: 195-203.
Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999; 19: 203-208.
McCreadie RG, Robertson LJ, Wiles DH. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry 1992; 160: 793-799.
Sachdev P. The epidemiology of drug- induced akathisia: Part I. Acute akathisia. Schizophr Bull 1995; 21: 431-449.
Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry 1981; 138: 297-309.
Halstead SM, Barnes TR, Speller JC. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 1994; 164: 177-183.
Sachdev P. The epidemiology of drug- induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull 1995; 21: 451-461.
Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63 (Suppl 4): 12-19.
Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676.
Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473-481.
Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
Papapetropoulos S, Wheeler S, Singer C. Tardive dystonia associated with ziprasidone. Am J Psychiatry 2005; 162: 2191.
Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never- medicated schizophrenic patients. Am J Psychiatry 1995; 152: 1724-1729.
Scherk H, Falkai P. [Changes in brain structure caused by neuroleptic medication]. Nervenarzt 2004; 75: 1112-1117.
Janicak PG, Beedle D. Medication-induced movement disorders. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2005.
Jaanson P. [Description of the treatment of schizophrenia spectrum psychosis outpatients using a questionnaire]. Eesti Arst 2002; 81:333–337.
Thomas M, Jankovic J. Psychogenic movement disorders: diagnosis and management. CNS Drugs 2004; 18: 437-452.
Rockville WG. ECDEU assessment manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338). US Department of Health, Education, and Welfare. NIMH Psychopharmacology Research Branch; 1976.
Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004; 161: 160-163.
Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry 1984; 145: 304-310.
Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry 1974; 37: 941-947.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.